Where mid-infrared spectroscopy meets medicine

4 Feb

Calendars and Schedules : congress 2019

This year Diafir will still travel a lot. Our next dates of congress and participation in scientific events. 10-14 Avril 2019 : EASL, Vienne, Autriche 14-16 Mai 2019 : MedTech Europe, Paris, France 5-7 Juin 2019 : National Infectiology Day, Lyon, France 12-15 Juin 2019 : EULAR, Madrid, Espagne 11-12 Juillet 2019 : NASH Symposium, Paris, France 8-12 Novembre 2019 : […]

20 Dec

DIAFIR in MARSEILLE (Photonic Roadshow)

The fourth event of the Photonic Roadshow was held in Marseille on November 17th. It is an understatement that the meetings were rich. Experts from all countries covered a wide range of topics ranging from medical market trends and needs to photonic technologies, to the transformation of regulatory requirements into value added for products. We […]


DIAFIR has been incepted in 2011 by a world-renowned team of researchers from Rennes 1 University, France.

DIAFIR has developed the SPID™ platform, a breakthrough proprietary device for patient screening triage. SPID™ analyses the entire metabolic signature spectrum of patient’s blood serum, within minutes, using mid-infrared spectroscopy.

Thanks to its platform, DIAFIR aims to develop and bring to market its revolutionary serum test NASHMIR® for NASH detection.

Our goal is to help save lives through early detection while being minimally invasive to the patient.


  • DIAFIR’s vision is to become the standard of care in the way people are routinely checked for NASH (early detection).
  • DIAFIR’s method is easy to implement and at a low cost, currently targeting the obese patients as the first choice for NASH detection.
  • Our proprietary platform SPID™ can be applied on other types of diseases (as a start we are focused on NASH and infectious arthropathies).